liu.seSearch for publications in DiVA
Endre søk
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
No excess long-term mortality in stage I-IIA Hodgkin lymphoma patients treated with ABVD and limited field radiotherapy
Uppsala Univ, Sweden.
Oslo Univ Hosp, Norway; KG Jebsen Ctr B Cell Malignancies, Norway.
Uppsala Univ, Sweden.
Karolinska Univ, Sweden.
Vise andre og tillknytning
2020 (engelsk)Inngår i: British Journal of Haematology, ISSN 0007-1048, E-ISSN 1365-2141, Vol. 188, nr 5, s. 685-691Artikkel i tidsskrift (Fagfellevurdert) Published
Abstract [en]

When treating limited stage classical Hodgkin lymphoma (cHL), balancing treatment efficacy and toxicity is important. Toxicities after extended-field radiotherapy are well documented. Investigators have aimed at reducing toxicity without compromising efficacy, mainly by using combined modality treatment (CMT), i.e. chemotherapy and limited-field radiotherapy. In some clinical trials, radiotherapy has been omitted. We evaluated 364 patients with stage I-IIA cHL treated between 1999 and 2005. Patients were treated with two or four cycles of doxorubicin, bleomycin, vinblastine and dacarbazine (ABVD) according to presence of risk factors, followed by 30 Gy limited-field (reduced compared to involved-field) radiotherapy. After a median follow-up of 16 years for survival, freedom from progression at five and ten years was 93% and overall survival at 5 and 10 years was 98% and 96%, respectively. Only two relapses, out of 27, occurred after more than 5 years. There was no excess mortality compared to the general population. Of the analysed subgroups, only patients with progression within five years showed significant excess mortality. The absence of excess mortality questions the concept of omitting radiotherapy after short-term chemotherapy, a strategy that has been associated with an elevated risk of relapse but not yet with a proven reduced long-term excess mortality.

sted, utgiver, år, opplag, sider
WILEY , 2020. Vol. 188, nr 5, s. 685-691
Emneord [en]
limited stage; hodgkin lymphoma; relative survival
HSV kategori
Identifikatorer
URN: urn:nbn:se:liu:diva-164365DOI: 10.1111/bjh.16232ISI: 000516520300015PubMedID: 31612478OAI: oai:DiVA.org:liu-164365DiVA, id: diva2:1416030
Merknad

Funding Agencies|Swedish Cancer SocietySwedish Cancer Society; Stiftelsen Onkologiska Klinikens i Uppsala Forskningsfond; Uppsala University; Nordic Cancer Union

Tilgjengelig fra: 2020-03-20 Laget: 2020-03-20 Sist oppdatert: 2020-03-20

Open Access i DiVA

Fulltekst mangler i DiVA

Andre lenker

Forlagets fulltekstPubMed

Søk i DiVA

Av forfatter/redaktør
Fohlin, HelenaAkesson, Lisa
Av organisasjonen
I samme tidsskrift
British Journal of Haematology

Søk utenfor DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric

doi
pubmed
urn-nbn
Totalt: 15 treff
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf